Professor Riste?rd ? Laoide:

The cancer programme has put much investment in the past couple of years into survivorship and psycho-oncology. Hopefully, we will have a full complement of psycho-oncology multidisciplinary team, MDT, in each of our cancer centres this year. That has been a result of recent investment. We also put a significant number of people into the survivorship pathway. We are looking at things such as self-stratified managed follow-up of patients. These are patients where it is their will and decision that they will work with a nurse specialist and perhaps a cancer care worker so that they have an organised follow-up surveillance package, which shows them, for example, when they get their CAT scan follow-up and when they need their blood test. They do not need to be coming into hospital for this. This is all organised and they are told about their red flag signs so that they get immediate access if a red flag raises. It just means that they are not coming into outpatient departments to sit to meet a consultant or somebody. It is called self-stratified, managed follow-up. It is being rolled out for prostate cancer in the first half of this year and we hope to roll it out for the other cancers in the next 12 to 18 months.